Pfizer India (PFIZER) Q4 24/25 earnings summary

Executive summary

• Audited financial results for the year ended March 31, 2025, were approved, showing strong profitability and cash flow generation.

• Board recommended a total dividend of Rs. 165 per share, including special dividends for the 75th year in India and a gain on asset transfer.

• No modifications in the auditor's report; financials present a true and fair view.

Financial highlights

• Revenue from operations for FY25 was Rs. 2,281.35 crore, up from Rs. 2,193.17 crore year-over-year.

• Net profit for FY25 stood at Rs. 767.60 crore, a significant increase from Rs. 551.33 crore in FY24.

• Earnings per share for FY25 were Rs. 167.79, up from Rs. 120.51 in FY24.

• Cash and cash equivalents at year-end were Rs. 495.07 crore, up from Rs. 112.00 crore last year.

• Total equity increased to Rs. 4,217.41 crore from Rs. 3,595.54 crore year-over-year.

Outlook and guidance

• The Board has recommended a final and special dividend, subject to shareholder approval at the upcoming AGM.

• 74th AGM scheduled for July 21, 2025, to be held via video conferencing.